文献速递脑血管病

FIP1L1-PDGFRA相关高嗜酸性粒细胞综合征是可治的分水岭梗死病因

FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
PubMed 文献 · Stroke · 2021-07-26

多数影像显示双侧分水岭区多发梗死(69%),62.5%按TOAST分类为不明病因。15例接受伊马替尼治疗,中位随访4.5年,仅3例卒中复发。

要点

  • 不明原因缺血性卒中伴高嗜酸性粒细胞增多需考虑F/P阳性克隆性HES。
  • 双侧分水岭区多发梗死是该类卒中的典型影像模式。
  • 伊马替尼治疗可显著降低卒中复发风险。

核心结论

  • F/P阳性克隆性高嗜酸性粒细胞综合征是 unexplained ischemic stroke 伴高嗜酸性粒细胞增多(尤其多发性皮质分水岭分布)时需考虑的诊断,并应尽快启动伊马替尼治疗。

研究设计与样本

  • 基于151例F/P相关克隆性高嗜酸性粒细胞综合征患者的全国性回顾性队列,筛选有缺血性卒中临床病史者并加入2例额外病例进行分析。

主要发现

  • 中位NIHSS为4(范围1–6)。
  • 多数脑影像显示双侧分水岭分布多发梗死(69%)。
  • 心脏受累常见(50%),但仅1例证实心脏血栓。
  • 按TOAST分类,62.5%的卒中为不明病因。

关键数值与推荐

  • 15例接受伊马替尼治疗,中位随访4.5年,仅3例卒中复发(为心源性栓塞或出血事件,与首次发作无关)。

临床怎么用

  • 对不明原因缺血性卒中伴高嗜酸性粒细胞增多者,尤其影像呈多发性皮质分水岭分布时,应检测FIP1L1-PDGFRA融合。
  • 确诊F/P阳性克隆性HES后应尽快启动伊马替尼治疗以降低卒中复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Ischemic stroke has been reported in various conditions associated with eosinophilia. FIP1L1-PDGFRA fusion ([Fip1-like 1-platelet-derived growth factor receptor alpha]; F/P) leads to the proliferation of the eosinophilic lineage and thus to a clonal hypereosinophilic syndrome that is highly responsive to imatinib. METHODS: We previously reported on a nationwide retrospective study of 151 patients with F/P-associated clonal hypereosinophilic syndrome. Patients from this cohort with a clinical history of ischemic stroke (as well as 2 additional cases) were further analyzed to better define their clinical picture and outcomes. RESULTS: Sixteen male patients (median age, 51 [43–59] years) with low-to-intermediate cardiovascular risk were included. Median National Institutes of Health Stroke Scale was 4 (range, 1–6). Most cerebral imaging disclosed multiple bilateral infarctions of watershed distribution (69%). Despite frequent cardiac involvement (50%), cardiac thrombus was evidenced in a single patient and, according to the TOAST classification (Trial of ORG 10172 in Acute Stroke Treatment), 62.5% of strokes were presumably of undetermined etiology. Among the 15 patients treated with imatinib, and after a median follow-up of 4.5 years, stroke recurred in only 3 patients (consisting of either cardio embolic or hemorrhagic events, unrelated to the first episode). CONCLUSIONS: F/P+ clonal hypereosinophilic syndrome is a diagnosis to consider in patients with unexplained ischemic stroke and hypereosinophilia (especially in the setting of multiple cortical borderzone distribution) and warrants prompt initiation of imatinib.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Tennenbaum J, Groh M, Venditti L, et al. FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction. Stroke. 2021. PMID: 34304603. doi:10.1161/STROKEAHA.121.034191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。